Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec;51(4):347-349.
doi: 10.1007/s13139-017-0486-5. Epub 2017 Jul 25.

Altered Biodistribution of 99mTc-DPD on Bone Scan After Intravenous Iron Supplement

Eonwoo Shin  1 , Minyoung Oh  1 , Changhwan Sung  1 , Ki-Hun Kim  2 , Jin-Sook Ryu  1
Affiliations
Case Reports

Altered Biodistribution of 99mTc-DPD on Bone Scan After Intravenous Iron Supplement

Eonwoo Shin et al. Nucl Med Mol Imaging. 2017 Dec.

Abstract

We report a case with altered biodistribution of 99mTc-dicarboxypropane diphosphonate (99mTc-DPD) on whole body bone scan after intravenous iron supplement therapy. A 47-year-old male patient who had recently been detected with a hepatic mass suggestive of hepatocellular carcinoma underwent bone scan as staging work-up before surgery. Bone scan images at 3 h after injection of 99mTc-DPD demonstrated unusually increased blood pool activities in the heart, liver, and spleen with usual skeletal uptakes. The patient had been treated for severe anemia from hemorrhoid with two intravenous administration of ferric hydroxide carboxymaltose complex at approximately 22 h and 2 h prior to the 99mTc-DPD injection, which we consider as the most probable cause of altered biodistribution of 99mTc-DPD.

Keywords: 99mTc-DPD; Biodistribution; Bone scan; Iron supplement.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsEonwoo Shin, Minyoung Oh, Changhwan Sung, Ki-Hun Kim, and Jin-Sook Ryu declare that they have no conflicts of interest.All procedures performed in this study involving human participants were in accordance with the ethical standards of the respective institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.

Figures

Fig. 1
Fig. 1
Anterior (left) and posterior (right) view of preoperative 99mTc-DPD bone scan showing unusual, diffusely increased activities in the heart, liver, and spleen. A focal increased uptake in the left temporal bone may be a benign bone lesion rather than skeletal metastasis
See this image and copyright information in PMC

References

    1. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953. doi: 10.1200/JCO.2004.08.181. - DOI - PubMed
    1. Bergqvist L, Brismar J, Cederquist E, Darte L, Naversten Y, Palmer J. Clinical comparison of bone scintigraphy with 99Tcm-DPD, 99Tcm-HDP and 99Tcm-MDP. Acta Radiol Diagn (Stockh) 1984;25:217–223. doi: 10.1177/028418518402500310. - DOI - PubMed
    1. Vorne M, Vahatalo S, Lantto T. A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents. Eur J Nucl Med. 1983;8:395–397. doi: 10.1007/BF00253214. - DOI - PubMed
    1. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med. 1994;21:348–356. doi: 10.1007/BF00947972. - DOI - PubMed
    1. Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010;40:220–241. doi: 10.1053/j.semnuclmed.2010.02.004. - DOI - PubMed

Publication types